Phaseline

Targets › HSP90AB1

HSP90AB1 (Heat shock protein HSP 90-beta): drug programs, companies and trials

3 programs from 3 companies in 3 trials: 2 Phase 1, 1 Phase 2; Oncology; next expected readout Dec 2026.

Molecular chaperone that promotes the maturation, structural maintenance and proper regulation of specific target proteins involved for instance in cell cycle control and signal transduction. Undergoes a functional cycle linked to its ATPase activity. (UniProt, P08238)

Open in Phaseline: the race on HSP90AB1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
QuantumLeap Healthcare CollaborativeGanetespib
Heat shock protein HSP90 inhibitor
HSP90AA1, HSP90AB1Phase 2Breast NeoplasmsDec 2030
Taiho PharmaceuticalPimitespib
HSP90 inhibitor
HSP90AA1, HSP90AB1Phase 1Gastrointestinal Stromal TumorsDec 2026
H. Lee Moffitt Cancer Center and Research InstituteXL888
HSP90 inhibitor
HSP90AB1, HSP90AA1Phase 1Melanoma–

Conditions

Breast Neoplasms (1) Gastrointestinal Stromal Tumors (1) Melanoma (1)

Modalities

small molecule (2), mixed (1)

Companies

QuantumLeap Healthcare Collaborative (1) Taiho Pharmaceutical (1) H. Lee Moffitt Cancer Center and Research Institute (1)

Related targets

HSP90AA1 (3)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.